Company: WHWK
Filing Date: 2025-04-04
Form Type: CORRESP
Source: 0001193125-25-073631
Chunk: 0

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-04
Form: CORRESP
Chunk 0
---
April 4, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Lauren Hamill

| Re: | Whitehawk Therapeutics, Inc. |

Registration Statement on Form S-3 File No. 333-286284 Acceleration Request

| Requested Date: |     | April 8, 2025                                                |
|:----------------|:----|:-------------------------------------------------------------|
| Requested Time: |     | 4:00 p.m. Eastern Time, or as soon thereafter as practicable |

Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Whitehawk Therapeutics , Inc. (the “ Company”) hereby requests that its Registration Statement on Form S-3(File No. 333-286284)(the “ Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Robert Wernli at (619) 361-4805.

| Sincerely,                   |     |                            |
| WHITEHAWK THERAPEUTICS, INC. |     |                            |
| By:                          |     | /s/ David J. Lennon, Ph.D. |
|                              |     | David J. Lennon, Ph.D.     |
|                              |     | Chief Executive Officer    |

| cc: | Stephen Rodin, Whitehawk Therapeutics, Inc. |

Dan Koeppen, Wilson Sonsini Goodrich & Rosati Robert Wernli, Wilson Sonsini Goodrich & Rosati